Latest Pharma Insights
Ebola Outbreak Drives Medical Device Makers to Mobilize PCR Tests and Blood-Filtration Technology
20/20 Biolabs, Co-Diagnostics and Aethlon mobilize PCR assays, lab capacity, and blood-filtration technology against the Bundibugyo strain, as world governments update their threat assessments and responses.
Medtech Insight - May 25, 2026
20/20 Biolabs, Co-Diagnostics and Aethlon mobilize PCR assays, lab capacity, and blood-filtration technology against the Bundibugyo strain, as world governments update their threat assessments and responses.
Medtech Insight - May 25, 2026
Aurobindo On US Atopic Dermatitis Drug Launch, Biologics Manufacturing For Merck
Aurobindo revealed plans to launch an Otsuka-licensed NCE to treat atopic dermatitis in the US in the second quarter of FY27 and the strategy behind significant capacity build for anchor partner Merck's biologics.
Scrip - May 25, 2026
Aurobindo revealed plans to launch an Otsuka-licensed NCE to treat atopic dermatitis in the US in the second quarter of FY27 and the strategy behind significant capacity build for anchor partner Merck's biologics.
Scrip - May 25, 2026
AstraZeneca, Daiichi Gain Edge On First-line Triple Negative Breast Cancer With Datroway Approval
Datroway’s first-line TNBC approval strengthens competition in the TROP2 ADC market as rivals including Gilead advance therapies into earlier treatment settings.
Scrip - May 25, 2026
Datroway’s first-line TNBC approval strengthens competition in the TROP2 ADC market as rivals including Gilead advance therapies into earlier treatment settings.
Scrip - May 25, 2026
Biopharma M&A — Rothschild’s Bal On Dry Powder, PE Play and India’s Unique Calculus
Rothschild & Co India MD discusses the M&A outlook for biopharma amid global volatility, why biotechs are warming up to deals, PE appetite in India, and how the next generation of domestic family-controlled firms appears more pragmatic about value-creating opportunities.
Scrip - May 25, 2026
Rothschild & Co India MD discusses the M&A outlook for biopharma amid global volatility, why biotechs are warming up to deals, PE appetite in India, and how the next generation of domestic family-controlled firms appears more pragmatic about value-creating opportunities.
Scrip - May 25, 2026
MedTech Forum 2026 Interview: Bring The Innovation Launch Pad Back To Europe
MedTech Europe CEO Oliver Bisazza set out his hopes and aims for EU industry and markets during the MedTech Forum 2026 against a backdrop of cautious optimism in regulatory and strategy circles now the MDR/IVDR revision is getting EU co-legislator attention. Elsewhere, there remains work to do.
In Vivo - May 25, 2026
MedTech Europe CEO Oliver Bisazza set out his hopes and aims for EU industry and markets during the MedTech Forum 2026 against a backdrop of cautious optimism in regulatory and strategy circles now the MDR/IVDR revision is getting EU co-legislator attention. Elsewhere, there remains work to do.
In Vivo - May 25, 2026
MS Pharma Boosts Biosimilar Ambitions With Minority Equity Investment
Olayan Financing Company’s minority stake gives MS Pharma both the cash and the local network it needs to turn an ambitious MENA biosimilar strategy into real market presence in 2026.
Generics Bulletin - May 25, 2026
Olayan Financing Company’s minority stake gives MS Pharma both the cash and the local network it needs to turn an ambitious MENA biosimilar strategy into real market presence in 2026.
Generics Bulletin - May 25, 2026
Fresenius Celebrates US Federal Win On Ustekinumab
A federal contract in the US is set to bolster Fresenius Kabi’s Biopharma business, which grew by a quarter – and by 34% at constant currencies – in the first quarter of 2026, boosted by gains for tocilizumab and denosumab.
Generics Bulletin - May 25, 2026
A federal contract in the US is set to bolster Fresenius Kabi’s Biopharma business, which grew by a quarter – and by 34% at constant currencies – in the first quarter of 2026, boosted by gains for tocilizumab and denosumab.
Generics Bulletin - May 25, 2026
Accord’s Burden Moves Up To Chair At Medicines UK
UK generics and biosimilars association Medicines UK has announced the appointment of Accord’s Paul Burden as its new chair. He takes over the role from Sandoz’s Diane Di Gangi-Trench who will stay on for a further year as vice-chair.
Generics Bulletin - May 25, 2026
UK generics and biosimilars association Medicines UK has announced the appointment of Accord’s Paul Burden as its new chair. He takes over the role from Sandoz’s Diane Di Gangi-Trench who will stay on for a further year as vice-chair.
Generics Bulletin - May 25, 2026
Stock Watch: Bayer’s First-Quarter Rally And CSL’s Plunge Both Miss The Real Story
Bayer’s first-quarter crop science rally impressed the press for the wrong reasons. CSL’s surprise announcement, on the other hand, had been a long time coming, and an 11% stock drop reflected it.
Scrip - May 25, 2026
Bayer’s first-quarter crop science rally impressed the press for the wrong reasons. CSL’s surprise announcement, on the other hand, had been a long time coming, and an 11% stock drop reflected it.
Scrip - May 25, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: industry grapples with MFN fallout; rapid early trials fuel China deals; AbbVie looks to grow in neuroscience; is circular DNA the next big thing?; and a flunk for Regeneron’s fianlimab.
Scrip - May 25, 2026
In this week's episode: industry grapples with MFN fallout; rapid early trials fuel China deals; AbbVie looks to grow in neuroscience; is circular DNA the next big thing?; and a flunk for Regeneron’s fianlimab.
Scrip - May 25, 2026
Aurobindo On US Atopic Dermatitis Drug Launch, Biologics Manufacturing For Merck
Aurobindo revealed plans to launch an Otsuka-licensed NCE to treat atopic dermatitis in the US in the second quarter of FY27 and the strategy behind significant capacity build for anchor partner Merck's biologics.
Scrip - May 25, 2026
Aurobindo revealed plans to launch an Otsuka-licensed NCE to treat atopic dermatitis in the US in the second quarter of FY27 and the strategy behind significant capacity build for anchor partner Merck's biologics.
Scrip - May 25, 2026
AstraZeneca, Daiichi Gain Edge On First-line Triple Negative Breast Cancer With Datroway Approval
Datroway’s first-line TNBC approval strengthens competition in the TROP2 ADC market as rivals including Gilead advance therapies into earlier treatment settings.
Scrip - May 25, 2026
Datroway’s first-line TNBC approval strengthens competition in the TROP2 ADC market as rivals including Gilead advance therapies into earlier treatment settings.
Scrip - May 25, 2026
Biopharma M&A — Rothschild’s Bal On Dry Powder, PE Play and India’s Unique Calculus
Rothschild & Co India MD discusses the M&A outlook for biopharma amid global volatility, why biotechs are warming up to deals, PE appetite in India, and how the next generation of domestic family-controlled firms appears more pragmatic about value-creating opportunities.
Scrip - May 25, 2026
Rothschild & Co India MD discusses the M&A outlook for biopharma amid global volatility, why biotechs are warming up to deals, PE appetite in India, and how the next generation of domestic family-controlled firms appears more pragmatic about value-creating opportunities.
Scrip - May 25, 2026
Stock Watch: Bayer’s First-Quarter Rally And CSL’s Plunge Both Miss The Real Story
Bayer’s first-quarter crop science rally impressed the press for the wrong reasons. CSL’s surprise announcement, on the other hand, had been a long time coming, and an 11% stock drop reflected it.
Scrip - May 25, 2026
Bayer’s first-quarter crop science rally impressed the press for the wrong reasons. CSL’s surprise announcement, on the other hand, had been a long time coming, and an 11% stock drop reflected it.
Scrip - May 25, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: industry grapples with MFN fallout; rapid early trials fuel China deals; AbbVie looks to grow in neuroscience; is circular DNA the next big thing?; and a flunk for Regeneron’s fianlimab.
Scrip - May 25, 2026
In this week's episode: industry grapples with MFN fallout; rapid early trials fuel China deals; AbbVie looks to grow in neuroscience; is circular DNA the next big thing?; and a flunk for Regeneron’s fianlimab.
Scrip - May 25, 2026
Ebola Outbreak Drives Medical Device Makers to Mobilize PCR Tests and Blood-Filtration Technology
20/20 Biolabs, Co-Diagnostics and Aethlon mobilize PCR assays, lab capacity, and blood-filtration technology against the Bundibugyo strain, as world governments update their threat assessments and responses.
Medtech Insight - May 25, 2026
20/20 Biolabs, Co-Diagnostics and Aethlon mobilize PCR assays, lab capacity, and blood-filtration technology against the Bundibugyo strain, as world governments update their threat assessments and responses.
Medtech Insight - May 25, 2026
MHRA Outlines Plans For Medical Device CE Mark Recognition
At RAPS 2026, the MHRA announced updates on its consultation for indefinite CE Mark recognition and its own version of breakthrough device designation.
HBW Insight - May 22, 2026
At RAPS 2026, the MHRA announced updates on its consultation for indefinite CE Mark recognition and its own version of breakthrough device designation.
HBW Insight - May 22, 2026
People On The Move: Appointments at Cooper, Opella, Chiesi
A round up of the latest people moves: Cooper Consumer Health names Italy head and Iberia marketing lead; Opella appoints people head for Europe and LatAm; and Chiesi elects chair.
HBW Insight - May 22, 2026
A round up of the latest people moves: Cooper Consumer Health names Italy head and Iberia marketing lead; Opella appoints people head for Europe and LatAm; and Chiesi elects chair.
HBW Insight - May 22, 2026
FDA Will Miss May Allergen Labeling Rule Deadline – OCC Deputy Director
Deputy Director of the US FDA's Office of Cosmetics and Colors provided a MoCRA update during IBA's Spring 2026 Cosmetics Convergence conference in New York May 21.
HBW Insight - May 22, 2026
Deputy Director of the US FDA's Office of Cosmetics and Colors provided a MoCRA update during IBA's Spring 2026 Cosmetics Convergence conference in New York May 21.
HBW Insight - May 22, 2026
US Consumer Health Industry News Digest: Business, Regulation, Science
Weekly digest of US consumer health industry/marketplace news: Congress proposes adding supplements to HSA/FSAs; acting FDA foods program chief familiar to industry; PRE study guidance for formula industry; higher costs not new to industry; and ‘fundamental reset’ in longevity wellness.
HBW Insight - May 22, 2026
Weekly digest of US consumer health industry/marketplace news: Congress proposes adding supplements to HSA/FSAs; acting FDA foods program chief familiar to industry; PRE study guidance for formula industry; higher costs not new to industry; and ‘fundamental reset’ in longevity wellness.
HBW Insight - May 22, 2026
MS Pharma Boosts Biosimilar Ambitions With Minority Equity Investment
Olayan Financing Company’s minority stake gives MS Pharma both the cash and the local network it needs to turn an ambitious MENA biosimilar strategy into real market presence in 2026.
Generics Bulletin - May 25, 2026
Olayan Financing Company’s minority stake gives MS Pharma both the cash and the local network it needs to turn an ambitious MENA biosimilar strategy into real market presence in 2026.
Generics Bulletin - May 25, 2026
Fresenius Celebrates US Federal Win On Ustekinumab
A federal contract in the US is set to bolster Fresenius Kabi’s Biopharma business, which grew by a quarter – and by 34% at constant currencies – in the first quarter of 2026, boosted by gains for tocilizumab and denosumab.
Generics Bulletin - May 25, 2026
A federal contract in the US is set to bolster Fresenius Kabi’s Biopharma business, which grew by a quarter – and by 34% at constant currencies – in the first quarter of 2026, boosted by gains for tocilizumab and denosumab.
Generics Bulletin - May 25, 2026
Accord’s Burden Moves Up To Chair At Medicines UK
UK generics and biosimilars association Medicines UK has announced the appointment of Accord’s Paul Burden as its new chair. He takes over the role from Sandoz’s Diane Di Gangi-Trench who will stay on for a further year as vice-chair.
Generics Bulletin - May 25, 2026
UK generics and biosimilars association Medicines UK has announced the appointment of Accord’s Paul Burden as its new chair. He takes over the role from Sandoz’s Diane Di Gangi-Trench who will stay on for a further year as vice-chair.
Generics Bulletin - May 25, 2026
MedTech Forum 2026 Interview: Bring The Innovation Launch Pad Back To Europe
MedTech Europe CEO Oliver Bisazza set out his hopes and aims for EU industry and markets during the MedTech Forum 2026 against a backdrop of cautious optimism in regulatory and strategy circles now the MDR/IVDR revision is getting EU co-legislator attention. Elsewhere, there remains work to do.
In Vivo - May 25, 2026
MedTech Europe CEO Oliver Bisazza set out his hopes and aims for EU industry and markets during the MedTech Forum 2026 against a backdrop of cautious optimism in regulatory and strategy circles now the MDR/IVDR revision is getting EU co-legislator attention. Elsewhere, there remains work to do.
In Vivo - May 25, 2026